CVAC - CureVac Operating income before deduction of amortization

Graphic logo of curevac.com (CVAC)

A stable staff of RNA experts minimizes personnel risks, supporting the dynamics of EBITDA, which currently stands at approximately 0.00 for CureVac N.V. (CVAC). The business foundation is based on B2B/B2G supplies of mRNA therapies, while the development of thermostable drugs optimizes logistics costs. This chart visualizes the consolidation phases of cash flows from operating activities before taxes.

CVAC - CureVac Corp Operating profit before deduction of amortization over the range 11/23/2025 - 01/17/2026

CureVac (CVAC) - metric breakdowns and financial figures

- stock price and consensus target price:
Price Chart CureVac Pharma|CVAC - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization CureVac|CVAC - Total Company Value
- balance sheet equity data:
Accounting Value of a Share CureVac|CVAC - Company Net Assets|Market Capitalization to Book Value Ratio curevac.com|CVAC - Aggregate Company Assets
- debt level and financial liquidity data:
Total Debt to Capital Coefficient CureVac N.V.|CVAC - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio CureVac NV|CVAC - Company Total Debt|Debts to Book Capitalization CureVac|CVAC - Company Long-Term Debt|Company Short-Term Loans and Borrowings CureVac|Immediate Liquidity curevac.com
- earnings and market ratios statistics:
CVAC - Net Income|Expected Profit CureVac N.V.|CVAC - P/E Multiple|Forward P/E Multiple curevac.com|CVAC - PEG Multiple|Enterprise Value to EBITDA Ratio CureVac|CVAC - Operating profit before deduction of amortization|Earnings per share for the trailing year CureVac|CVAC - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months curevac.com|CVAC - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year CureVac N.V.
Fundamental company valuation:CVAC (CureVac Pharma)
Signature product of CureVac Corp

High costs associated with recruiting elite German mRNA scientists directly impact the operational efficiency of CureVac N.V. (CVAC). This metric measures actual cash flow from core operations minus production costs. It determines the business's ability to maintain its scientific foundation without external borrowing. A sharp decline in these values signals a risk of capital freeze. By analyzing quarterly EBITDA, investors assess the company's resilience to market volatility.

Competitors of CureVac N.V. (CVAC)

Gilead Corp - Profit before payment of interest, taxes and amortization|Cidara Therapeutics, Inc. - Operating profit EBITDA|Operating income before deduction of amortization novavax.com NVAX|Valneva (VALN) - Profit before payment of interest, taxes and amortization|Vir Biotechnology Inc - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization SIGA|Operating profit EBITDA Emergent Bio|Profit before payment of interest, taxes and amortization Atea Pharmaceuticals (AVIR)|Operating income before deduction of amortization invivyd.com|Operating profit EBITDA ENTA (Enanta Pharmaceuticals, Inc.)|INO - Operating profit before deduction of amortization|HLVX: Operating profit before deduction of amortization|KLRS - Operating profit EBITDA|dyadic.com (DYAI) - Profit before payment of interest, taxes and amortization|NanoViricides - Income before deduction of interest, taxes and amortization|TLPH (Talphera) - Operating profit EBITDA|Profit before interest, taxes and amortization Cocrystal Pharma Inc COCP|Operating profit before deduction of amortization TRAW (Traws Pharma, Inc.)|Profit before payment of interest, taxes and amortization DWTX (dwtx.com)|Operating profit EBITDA QLGN (Qualigen Therapeutics)|Operating profit EBITDA AlloVir Inc ALVR|VBI Vaccines Inc - Operating profit EBITDA|Virios Therapeutics (VIRI) - Operating profit before deduction of amortization|VXRT (vaxart.com) - Operating profit before deduction of amortization